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Assessment of diff erent instruments used as 
outcome measures in patients with fi bromyalgia
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ABSTRACT
Objective: To assess the different measure instruments used for patients with fi bromyalgia. Patients and methods: This 
study assessed 60 individuals participating in a clinical trial of cross-sectional cohort comparing the effects of exercises 
performed in water and on land. The following instruments were used: the Fibromyalgia Impact Questionnaire (FIQ) 
to assess the impact of the disease; the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) to assess 
quality of life; the Beck Depression Inventory to assess depression; and the Visual Analogue Scale (VAS) of pain. Those 
questionnaires were compared with the results obtained in a transitional Likert-type scale, the verbal scale for assessing 
change (VSAC), considered as a criterion of change in the assessment of other instruments. Results: The Spearman 
coeffi cient was used to study the correlation between the VSAC measure and the other instruments at two occasions 
(T1 and T2). At T1, a moderate correlation was observed between VSAC and VAS (r = 0.49), and between VSAC and 
FIQ (r = 0.41), and a negative correlation was observed between VSAC and the SF-36 domains pain (r = −0.49) and 
general health perception (r = −0.55), and the SF-36 physical component (r = −0.42). At T2, only the SF-36 domain 
vitality showed a weak negative correlation with VSAC (r = −0.27). Conclusion: Considering VSAC as gold standard, 
none of the instruments assessed could optimally identify a change in the health status of patients with fi bromyalgia.
Keywords: fi bromyalgia, questionnaires, quality of life. 
© 2012 Elsevier Editora Ltda. All rights reserved.
INTRODUCTION
Fibromyalgia (FM) is a syndrome characterized by chronic 
diffuse1 pain of unknown, probably multifactorial etiology,2–5 
sleep disorders, fatigue, and mood swings.6,7 Laboratory and 
imaging tests show neither tissue injury nor changes.8 Thus, 
the intensity, the impact on the patients’ quality of life, and the 
temporal or therapeutic intervention variations are subjective, 
diffi cult and imprecise.9
Measure instruments to quantify those clinical parameters 
should be carefully selected, because outcome measures should 
have adequate psychometric properties. To be signifi cant, 
the instrument should be sensitive to changes and clinically 
measurable, in addition to having high reliability and validity. 
Other aspects of those instruments, such as applicability, 
practicality and clarity, are also important.10 The only ques-
tionnaire specifi cally developed for FM, the Fibromyalgia 
Impact Questionnaire (FIQ), although validated only in a 
limited way,11–16 is widely used in several countries. In 2009, a 
study,17 estimating the minimal clinically important difference 
(MCID) for the FIQ, concluded that a 14% change in the FIQ 
total score is clinically relevant, reinforcing its use in research 
and clinical settings.
Selecting adequate outcome measures for evaluating 
changes due to interventions in FM in clinical trials on that 
disease is extremely diffi cult, because of the subjectivity 
and heterogeneity of the FM symptoms.18 In addition, physi-
ological, cognitive-verbal, and behavioral variables need to be 
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investigated. In a review of 24 clinical trials involving patients 
with FM, a great diversity of parameters was used, but the 
evaluation criteria were not consistently used in any of the 
trials.19 A more recent systematic review,20 comparing the most 
used variables in clinical trials with the OMERACT (Outcome 
Measures in Rheumatoid Arthritis Clinical Trials) proceedings 
for FM,21 has concluded that each OMERACT domain has an 
instrument that seems sensitive to change.
A consensus has not been achieved on the adequate gold 
standard for assessing clinical improvement resulting from 
different therapeutic interventions in FM, especially in the 
Brazilian population.22 Considering that there are no objective 
measures identifying patients’ improvement, subjective mea-
sures such as questionnaires assessing the quality of life, impact 
of the disease, and pain scales have been used. Regarding 
subjective symptoms, the patient’s perception is extremely 
important, because it comprises the complex assessment of the 
multiple domains that affect the individual’s biopsychosocial 
integrity.23 The information provided by patients regarding 
their health condition should be considered the gold standard 
to guide their treatment.24–27 Thus, this study aimed at assess-
ing the correlation between measure instruments used in the 
FM treatment and the objective questionnaire provided by the 
patient, assuming that the latter is a more sensitive parameter.
PATIENTS AND METHODS
Sample
The patients of this study were recruited from a clinical trial 
assessing the effects of exercise performed in water and that 
performed on land by women diagnosed with FM. The 60 
female patients participating in this study met the American 
College of Rheumatology (ACR) criteria for FM. They were 
systematically selected from the Rheumatology Outpatient 
Clinic of the Federal University of São Paulo (Unifesp). Of 
the 60 female patients included, only 51 completed all assess-
ments, comprising the object of this analysis.
Procedures
The project was approved by the Ethics Committee of the 
Unifesp, as participants provided written informed consent. 
The patients selected were assessed by use of the following 
instruments: (a) the FIQ,9 a questionnaire assessing the impact 
of the disease, and whose scoring is directly proportional to 
that impact – the higher the score, the worse the health condi-
tion. That questionnaire comprises 10 questions and quantifi es 
functional disability, pain intensity, sleep disorders, anxiety, 
depression, and well-being over the past week; (b) the Medical 
Outcomes Study 36-item Short-Form Health Survey (SF-36), 
an instrument validated for the Brazilian population,28 assessing 
quality of life. The SF-36 is divided into two components: the 
physical component, which determines the patient’s physical 
status by assessing the domains physical functioning, physi-
cal role, pain, and general health perceptions; and the mental 
component, which reveals the patient’s psychoemotional 
status by assessing the domains vitality, emotional role, social 
functioning, and mental health. In the SF-36, a higher score in-
dicates better health status; (c) the Beck Depression Inventory, 
comprising 21 questions that assess the patient’s depression 
status – the higher the score, the worse the depression; and (d) 
the Visual Analogue Scale (VAS) of pain, according to which 
patients classify their pain in a 0–10 numeric scale, the highest 
score corresponding to the worst pain possible. The assess-
ments were performed at the beginning of treatment (T0), at the 
eighth week (T1), and at the fi fteenth week of treatment (T2).
Patient’s perspective was assessed based on a transitional 
fi ve-point Likert scale, the verbal scale for assessing change 
(VSAC), as follows: 1, signifi cant improvement; 2, moderate 
improvement; 3, mild improvement; 4, no improvement; and 
5, worsening. It served as reference (gold standard) for global 
perception of change.
All instruments were applied by an examiner blinded to 
the patient’s therapeutic group. 
Statistical analysis
The following statistical methods were used to assess this 
study’s results: (a) descriptive statistics, to analyze demo-
graphic and clinical variables (mean and standard deviation); 
(b) Spearman coeffi cient, to assess the correlation between 
the scores of change of the different instruments used and 
VSAC. The values used in such comparisons originated from 
the difference between the scorings at T0 and T1 for each 
questionnaire and the VAS – that is, between the fi rst (T0) 
and second assessment (T1). Then, those fi nal values were 
compared with VSAC at T1. The VSAC at T2 was compared 
with the difference between the scorings at T1 and T2 for the 
questionnaires and the VAS. 
In addition, (c) linear regression analysis was used to assess 
which of the measures better relates to the change perceived by 
patients at T1 and T2. In addition, (d) the magnitude of the ef-
fect of each instrument was calculated by dividing the mean of 
the baseline scores until the eighth week (T1) by the standard 
deviation of the baseline scores. This method was used to evalu-
ate the intensity of change, indicating the MCID. The analyses 
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were performed according to a protocol – thus, the size of the 
sample used for the statistical calculations was the number of 
patients completing all measure instruments at all assessments.
RESULTS
Of the 60 female patients selected for the study, 51 responded 
to all instruments at all assessments. Figure 1 shows the clas-
sifi cation score of the VSAC at T1 and T2. Table 1 shows the 
mean values and the respective standard deviations obtained 
in the FIQ, Beck Depression Inventory, VAS and SF-36 at 
T0, T1 and T2.
Table 1
Mean (standard deviation) of the FIQ, Beck Depression 
Inventory, VAS and SF-36 at T0, T1 and T2
T0 T1 T2
FIQ 63.29 (13.86) 43.28 (19.36) 38.07 (19.46)
Beck 18.60 (9.11) 11.25 (10.25) 9.58 (9.49)
VAS 8.27 (1.55) 5.85 (2.32) 5.05 (2.42)
SF-36/PF 57.41 (21.28) 62.91 (25.59) 66.00 (29.52)
SF-36/PR 18.75 (30.05) 43.33 (41.90) 53.75 (45.29)
SF-36/PA 31.66 (15.94) 42.91 (21.50) 49.63 (27.48)
SF-36/VT 30.91 (18.67) 47.41 (23.17) 49.16 (28.24)
SF-36/GH 45.81 (19.64) 53.21 (25.34) 54.63 (28.36)
SF-36/SF 54.37 (30.77) 71.82 (33.54) 69.16 (37.42)
SF-36/ER 38.33 (41.54) 55.00 (42.88) 56.66 (45.22)
SF-36/MH 45.40 (22.29) 56.93 (26.90) 57.60 (30.80)
SF-36/PCOMP 35.08 (6.93) 41.16 (7.68) 44.72 (8.59)
SF-36/MCOMP 38.27 (12.84) 46.22 (11.85) 47.25 (12.62)
PF: physical functioning; PR: physical role; PA: pain; VT: vitality; GH: general health perception; 
SF: social functioning; ER: emotional role; MH: mental health; PCOMP: physical component; 
MCOMP: mental component.
Table 2
Correlation of the VSAC1 measure with the difference between 
the fi rst and second assessments of FIQ, Beck Depression 
Inventory, VAS and SF-36 domains and components 
VSAC1 r P
FIQ   0.41 0.002**
Beck   0.32 0.02*
VAS   0.49 0.001**
PF/SF-36 −0.23 0.09
PR/SF-36 −0.28 0.04*
PA/SF-36 −0.49 0.001**
VT/SF-36 −0.29 0.03*
GH/SF-36 −0.55 0.001**
SF/SF-36 −0.26 0.06
ER/SF-36 −0.17 0.06
MH/SF-36 −0.31 0.02*
PCOMP/SF-36 −0.42 0.002**
MCOMP/SF-36 −0.25 0.06
**Signiﬁ cant correlation P > 0.01; *Signiﬁ cant correlation P > 0.05. r: Spearman correlation coefﬁ cient.
Table 3
Correlation of the VSAC2 measure with the difference between 
the second and third assessments of FIQ, Beck Depression 
Inventory, VAS and SF-36 domains and components
VSAC2 r P
FIQ   0.07 0.62
Beck −0.18 0.19
VAS   0.18 0.18
PF/SF-36 −0.1 0.47
PR/SF-36 −0.13 0.35
PA/SF-36 −0.17 0.23
VT/SF-36 −0.27 0.04*
GH/SF-36 −0.03 0.8
SF/SF-36 −0.76 0.59
ER/SF-36 −0.08 0.55
MH/SF-36   0.02 0.86
PCOMP/SF-36 −0.12 0.38
MCOMP/SF-36 −0.09 0.52
**Signiﬁ cant correlation P > 0.01; *Signiﬁ cant correlation P > 0.05. r: Spearman correlation coefﬁ cient.
The Spearman correlation coeffi cient revealed a signifi cant 
correspondence of the VSAC with the following at T1: the 
pain VAS (P < 0.001); the FIQ; and SF-36 domains pain and 
general health perception; and the SF-36 physical component 
(Table 2). At T2, the only variable showing statistically sig-
nifi cant correlation with VSAC was the SF-36 domain vitality 
(P = 0.04) (Table 3).
The simple linear regression analysis revealed, at T1, a 
statistically signifi cant correlation of VSAC with the VAS for 
Figure 1
Performance of the verbal scale for assessing change at T1 
and T2.
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pain (P = 0.001) and the SF-36 domain general health percep-
tion (P < 0.001) (Table 4). Table 4 also shows that, at T2, the 
only statistically signifi cant variable was the SF-36 domain 
vitality (P = 0.023). 
Based on the calculation of the magnitude of the effect 
(ME), VAS proved to be the most statistically signifi cant 
parameter to measure change (ME = –1.60), followed by FIQ 
(ME = –1.44). Table 5 shows the other important statistically 
signifi cant parameters to measure change.
DISCUSSION
Studies on FM have used different measures and instruments 
to assess therapeutic performance, hindering the attempts of 
extrapolation or comparison between treatments. At the same 
time, the large number of parameters studied makes the as-
sessments exhausting and redundant.
This study compared the results of the measuring instru-
ments FIQ, Beck Depression Inventory, SF-36 and pain VAS 
with the fi ve-point Likert-like comparative transitional scale, 
the VSAC perceived by the patient and used as gold standard. 
Global classifi cations of symptom change provided by patients 
are considered a valid external criterion23–27 and have been re-
cently applied to populations with FM.21,29,30 While completing 
the VSAC, the patient translated her impression of improve-
ment as a general aspect; the relationship of that answer with 
other instruments could indicate which aspects infl uenced the 
impression of improvement. At the fi rst assessment, the VSAC 
correlated with the SF-36 domains of pain and general health 
perception, the SF-36 physical component, in addition to the 
FIQ and the pain VAS. 
Dunkl et al.25 have reported results similar to ours, with 
correlation between the VSAC and FIQ. In our study, although 
to a lesser extent, a correlation was also observed with the 
SF-36 domains physical role, mental health, and vitality, and 
the Beck Depression Inventory. The result of the regression 
analysis confi rms the SF-36 domain general health perception 
and the pain VAS as important variables. Thus, the change in 
pain intensity, in general health status and in physical well-
being are fundamental aspects for the patient’s impression of 
improvement, especially in the initial treatment. In the second 
assessment provided by the patient, only the SF-36 domain 
vitality proved to have any relationship with the subjectivity of 
improvement. This can show that, after the initial improvement, 
aspects other than pain and general health status begin to have 
more infl uence on the subjective impression of improvement. 
Then, vitality begins to have more importance. 
One possible explanation for the difference found in the 
relationship between the instruments in the fi rst and second 
data comparison would be the intensity of changes. Thus, 
patients would only perceive changes in the aspects they 
consider important to contribute to the impression of im-
provement if that had a greater intensity. That statement is 
based on the fact that, most of the instruments used showed 
an improvement, sometimes small, not only between the fi rst 
and second assessments, but also between the second and 
third assessments. The time interval between the application 
of the instruments and the minimum difference necessary 
Table 4
Linear regression analysis showing the correlation between 
VSAC1 and VSAC2 and the other instruments
VSAC1 Bª Standard error Betaº P
VAS   0.135 0.038   0.4 0.001
GH/SF-36 −2.27 0.006 −0.45 0.001
VSAC2 Bª Standard error Betaº P
VIT/SF-36 −1.87 0.008 −0.32 0.02
ªNon-standardized correlation coefﬁ cient; ºStandardized correlation coefﬁ cient.
Table 5
Magnitude of the effect (ME) calculated for all instruments
Mean Standard deviation ME
VAS1   8.27   1.55 −1.6*
VAS2   5.78   2.32 0.31
PF1/SF-36 57.05 20.42 0.57
PF2/SF-36 68.72 17.91 0.4  
PR1/SF-36 21.07 31.76 0.92*
PR2/SF-36 50.49 41.37 0.29
PA1/SF-36 33.11 15.67 0.95*
PA2/SF-36 48.01 16.69 0.56
GH1/SF-36 48.13 18.74 0.55
GH2/SF-36 58.54 20.66 0.19
VIT1/SF-36 31.96 18.74 1.09*
VIT2/SF-36 52.25 18.68 0.27
SF1/SF-36 56.37 30.85 0.73
SF2/SF-36 79.16 25.33 0.02
ER1/SF-36 41.83 42.6 0.41
ER2/SF-36 59.47 42.32 0.15
MH1/SF-36 49.33 21.08 0.62
MH2/SF-36 62.5 22.25 0.18
FIQ1 63.29 13.86 −1.44*
FIQ2 43.28 19.36 −0.26
Beck1 18.6   9.11 −0.8
Beck2 11.25 10.25 0.16
*Statistically signiﬁ cant values (ME > 0.8).
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to identify changes might also have infl uenced the results. 
According to Stratford,31 the lack of a gold standard for at-
tributes such as functional disability generates methodologi-
cal dilemma. Beaton27 has reported that , in addition to the 
already established psychometric properties, the challenge of 
interpretability should also be faced. Thus, using the MCID 
is required. For determining MCID, not only the patient’s 
and physician’s perspectives should be considered, but also 
the methodological approach and the patient’s health status 
at the beginning of treatment. However, a greater number of 
methodological studies are required to determine the best 
way to quantify MCID. Regarding FIQ, a study29 has con-
cluded that a 14% change in the fi nal score would determine 
a MCID. Specially for FM, that can be of great clinical value, 
considering the subjectivity and variability of the symptoms.
In the present study, the ME was calculated for each instru-
ment as a way to determine MCID. On the fi rst assessment, the 
ME was clinically important for the SF-36 domains vitality, 
pain and physical role, and the Beck Depression Inventory, in 
addition to the FIQ and pain VAS. None of these were clinically 
important on the second assessment. Thus, the validity of the 
numerical interpretation of the ME in FM should be questioned, 
because that effect not always represents a true MCID.
Based on our data, pain remained as a central aspect for 
the impression of change on the health status. Pain is basically 
a subjective symptom, associated with the interaction of the 
physical, psychic and cultural dimensions involved in its mani-
festation, what makes its measurement diffi cult. However, our 
study revealed that, when monitoring the patient in a clinical 
setting, the use of a VSAC proved to suffi ce. In clinical tri-
als, other instruments can be used depending on the need for 
specifi c data in different aspects of the spectrum of the patient/
disease relationship. It is worth noting that each instrument 
assesses an individual’s different dimension, which might 
explain the lack of more correlation between the instruments, 
generating the need to choose not only an instrument to assess 
the therapeutic response, but, depending on the objective, to 
select the most adequate instrument.
It is worth emphasizing that, although the several instru-
ments, such as pain VAS, FIQ, SF-36 and Beck Depression 
Inventory, showed a ME over 0.8, indicating effective mag-
nitude, none of them could detect changes in the patients’ 
health status at T2 as compared with the VSAC. Thus, the 
psychometric properties of the instruments are not ideal for 
FM. Wolfe32 has proposed a version of the Health Assessment 
Questionnaire (FHAQ), which should be further studied and 
validated to be used in FM protocols.
CONCLUSION
Considering the VSAC as gold standard, none of the instru-
ments assessed was able to ideally capture a change in the 
FM patient’s health status. We emphasize the importance of 
assessing the psychometric properties of those instruments, 
in addition to studying the use of other instruments in clinical 
trials involving patients with FM.
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